In Depth 5 Nov 2024
From consumer health to pure biopharma: Inside Sanofi’s strategic shift
Delve into Sanofi’s “play to win” strategy as investments are ramping up after their consumer health division’s divestment.
About
After I graduated with a master’s degree in European Law from the
University of Tours, I decided to study journalism at the All Media
Journalism Institute of Lille. During this time, I discovered the healthcare
innovation ecosystem and enjoyed writing about it for Eurasanté, a French
healthcare cluster. I am interested in different subjects other than
healthcare and biotechnology: cinema, sports, photography… Journalism
had always been at the back of my mind, and I am delighted to write for
Labiotech as a junior reporter. When I am not working you might find me on the tennis court or picking up the next piece of furniture I will renovate.
Articles by Jules Adam
In Depth 1 Nov 2024
Can AI cure Alzheimer’s disease?
A couple of weeks back, we took a look at how artificial intelligence (AI) has had a transformative impact on cancer research. Today, we take a look at how AI tools help tackle another formidable challenge of modern biotech, Alzheimer’s disease. “Alzheimer’s is an incredibly complex disease with numerous factors at play. You have the […]
News and Trends 31 Oct 2024
Halloween biotech stories: Unveiling scientists’ worst fears
What are scientists scared of? Delve into three biotech sci-fi-inspired scenarios that might make you fear progress.
News and Trends 24 Oct 2024
Fighting severe epilepsies: A new era for Dravet syndrome treatment?
Delve into the field of severe epilepsies as new treatments for Dravet syndrome are progressing through the pipeline.
News and Trends 21 Oct 2024
Turning back time with cellular reprogramming: Shift raises $16 million in seed funding
As Shift Bioscience raises $16 million in seed funding, delve into the field of cellular reprogramming to tackle age-related diseases.
In Depth 18 Oct 2024
The AI boom in cancer: Game-changer or just hype?
Is AI just hype or a game-changer? Delve into AI’s contribution to oncology, from diagnostics to drug discovery and personalized treatment.
ADVERTISEMENT
ADVERTISEMENT
News and Trends 15 Oct 2024
Booster launches to treat neurodegenerative diseases with proteasome activation
Discover Booster Therapeutics’ novel proteasome activation approach to neurodegenerative diseases as it launches with $15 million.
Expert Advice 11 Oct 2024
How to build your biotech company in 2024 (according to founders)
Discover the insight successful biotech founders share with us to build your biotech company – from building your team to attracting funding.
In Depth 7 Oct 2024
Spinal cord injury: Are we getting closer to a treatment?
Delve into the spinal cord injury treatment landscape with a few pharmaceutical approaches that could tackle this complex condition.
News and Trends 3 Oct 2024
Resolution Therapeutics raises $85 million to advance its macrophage therapy
Find out about Resolution Therapeutics’ macrophage therapy, as it just raised $85 million in a series B round.
Best in Biotech 1 Oct 2024
Lithuania’s biotech: Six companies to put on your radar
Here are six companies at the forefront of Lithuania’s growing biotech scene, showcasing innovations in protein engineering and gene editing.
Podcast 27 Sep 2024
Harnessing the body’s natural targeted protein degradation system to treat diseases
Listen to our conversation with Andrew Hirsch, CEO at C4 Therapeutics, a leader in the targeted protein degradation field.
ADVERTISEMENT
